In general, TP53 aberrations in DLBCL are associated with poor outcomes, although the exact impact varies somewhat in different studies, owing probably to the adoption of different detection methods, which include immunohistochemical staining for p53, fluorescence in situ hybridization (FISH) for 17p13.1 (which contains TP53) deletion, and direct gene mutation analysis. The gene discussed is TP53; the disease is diffuse large B-cell lymphoma.